Trial · NCT02259127
Adverse events152
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 152
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Vascular disorders | Vascular disorders | Dolutegravir (>=14kg Cohort) | 1 | 350 | |
| serious | Vascular disorders | Vascular disorders | Standard of Care (>=14kg Cohort) | 0 | 357 | |
| serious | Vascular disorders | Vascular disorders | Dolutegravir (<14kg Cohort) | 0 | 42 | |
| serious | Vascular disorders | Vascular disorders | Standard of Care (<14kg Cohort) | 0 | 43 | |
| serious | Vascular disorders | Vascular disorders | Dolutegravir - ODYSSEY A (>=14kg Cohort) | 1 | 154 | |
| serious | Vascular disorders | Vascular disorders | Standard of Care - ODYSSEY A (>=14kg Cohort) | 0 | 157 | |
| serious | Vascular disorders | Vascular disorders | Dolutegravir - ODYSSEY B (>=14kg Cohort) | 0 | 196 | |
| serious | Vascular disorders | Vascular disorders | Standard of Care - ODYSSEY B (>=14kg Cohort) | 0 | 200 | |
| serious | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Dolutegravir (>=14kg Cohort) | 1 | 350 | |
| serious | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Standard of Care (>=14kg Cohort) | 2 | 357 | |
| serious | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Dolutegravir (<14kg Cohort) | 0 | 42 | |
| serious | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Standard of Care (<14kg Cohort) | 0 | 43 | |
| serious | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Dolutegravir - ODYSSEY A (>=14kg Cohort) | 0 | 154 | |
| serious | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Standard of Care - ODYSSEY A (>=14kg Cohort) | 1 | 157 | |
| serious | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Dolutegravir - ODYSSEY B (>=14kg Cohort) | 1 | 196 | |
| serious | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Standard of Care - ODYSSEY B (>=14kg Cohort) | 1 | 200 | |
| serious | Immune system disorders | Immune system disorders | Dolutegravir (>=14kg Cohort) | 1 | 350 | |
| serious | Immune system disorders | Immune system disorders | Standard of Care (>=14kg Cohort) | 0 | 357 | |
| serious | Immune system disorders | Immune system disorders | Dolutegravir (<14kg Cohort) | 0 | 42 | |
| serious | Immune system disorders | Immune system disorders | Standard of Care (<14kg Cohort) | 0 | 43 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02259127/events